Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers

Completed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes

In brief

RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic cancer. PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine and mitoxantrone in treating patients who have hematologic cancer.

Key facts

Study ID

NCT00015951

Run by

University of Maryland, Baltimore

Starts

2001-04-01

Expected to finish

2004-03-01

Last updated by the study team

2019-10-17

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Blood and Marrow Transplant Group of Georgia — Atlanta, Georgia, United States
• Marlene and Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.